Cancer survivors age faster than those who haven’t had the disease
As they are rising in number, more research is needed on how best to lengthen their lifespan
People who have had cancer naturally age faster than their peers who haven’t had the disease, finds a review of the available evidence, published in the online journal ESMO Open.
More research is therefore needed on how best to stave off the accelerated ageing process to lengthen their lifespan and improve the quality of their lives, suggest the researchers.
Thanks to more effective diagnosis and treatment, the number of cancer survivors is set to rise. Currently they number 30 million around the globe, but by 2025, around 19 million new diagnoses will be made every year, and most of these will produce long term survivors, they say.
Cancer survivors are more likely to develop long term conditions, and sooner than the general population. The list includes conditions, such as hormonal/gland disorders (endocrinopathies), heart problems, lower bone mineral density, lung scarring (pulmonary fibrosis), secondary cancers, and frailty.
This is most likely due to the damage caused by chemotherapy and radiotherapy to normal healthy tissues, which diminishes ‘physiological reserve’- the capacity in organs and biological body systems given to us at birth – and the body’s natural resilience to overcome internal and external biological stressors.
“While ageing prematurely is a better alternative to dying prematurely, a better understanding of what drives this process presents an opportunity for improvement,” state the researchers.
They therefore trawled databases for published evidence on the cellular processes involved in ageing and the potential impact of cancer treatments on these.
They found a wide range of side effects and late complications, which have implications not only for the individuals concerned, but also for health services. Among them:
The researchers emphasise that despite these undesirable side effects, cancer treatments are worthwhile for scores of patients with the disease, and that ageing is part of life.
But accelerated ageing, experienced by many cancer survivors as a direct consequence of their treatment, is something that can, and should be, minimised, they insist. For one thing, cancer survivors deserve it, and for another, it’s a public health issue, they say.
“We believe that cancer survivors deserve long term follow up for the mitigation of the late effects,” they write.
“Future research to better understand mechanisms of accelerated ageing-like phenotypes is essential for the oncology community as well as from a public health and health policy perspective,” they add.
“The ultimate goal of these studies will be to prevent late complications using early interventions, including lifestyle changes and medications.”
Review: Biology of premature ageing in survivors of cancer doi 10.1136/esmoopen-2017-000250
Journal: ESMO Open